← All trials
NCT05909397
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 9, 2023
- Primary completion
- Aug 28, 2028
- Completion date
- Jul 26, 2030
- First posted
- Jun 18, 2023
- Last posted
- Oct 27, 2023
- Enrollment
- 1180
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- PfizerLead sponsor
- PfizerStudy director
- Arvinas IncCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.